Erika Hamilton, Chair, Executive Committee Breast and Breast Program Lead at Sarah Cannon Research Institute, shared a post on X:
“TACTIVE-N: neoadj vepdeg vs. anastrazole
Tumor at baseline, wk 2, and at surgery (6mo)
Comparable results- Ki-67 declines by about 70% at 2 wks and further ~ 80% at surgery for both drugs
100% PgR H score decline with vepdeg.”
You Can Also Read:
ESMO 2025 Day 1 Highlights Not to Miss
ESMO 2025 Day 2 Highlights Not to Miss
